Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) EBITDA Margin % : 37.61% (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Parnell Pharmaceuticals Holdings's EBITDA for the six months ended in Dec. 2018 was $7.16 Mil. Parnell Pharmaceuticals Holdings's Revenue for the six months ended in Dec. 2018 was $19.03 Mil. Therefore, Parnell Pharmaceuticals Holdings's EBITDA margin for the quarter that ended in Dec. 2018 was 37.61%.

Parnell Pharmaceuticals Holdings EBITDA Margin % Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings EBITDA Margin % Chart

Parnell Pharmaceuticals Holdings Annual Data

Trend

Jun12

Jun13

Jun14

Dec15

Dec16

Dec17

Dec18

EBITDA Margin %

Get a 7-Day Free Trial

-59.61

-55.15

-80.00

-30.92

37.61

Parnell Pharmaceuticals Holdings Semi-Annual Data
	Jun12	Jun13	Jun14	Dec15	Dec16	Dec17	Dec18
EBITDA Margin %	Get a 7-Day Free Trial			-59.61	-55.15	-80.00	-30.92	37.61

Competitive Comparison of Parnell Pharmaceuticals Holdings's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Parnell Pharmaceuticals Holdings's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's EBITDA Margin % falls into.

Parnell Pharmaceuticals Holdings EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Parnell Pharmaceuticals Holdings's EBITDA Margin % for the fiscal year that ended in Dec. 2018 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2018 )	/	Revenue (A: Dec. 2018 )
	=	7.158	/	19.031
	=	37.61 %

Parnell Pharmaceuticals Holdings's EBITDA Margin % for the quarter that ended in Dec. 2018 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2018 )	/	Revenue (Q: Dec. 2018 )
	=	7.158	/	19.031
	=	37.61 %

Parnell Pharmaceuticals Holdings (OTCPK:PARNF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Parnell Pharmaceuticals Holdings EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015

Website

https://www.parnell.com

Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.